FDA-approved Drug for Relapsed Follicular Lymphoma in Adults
Copanlisib, a kinase inhibitor, has received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of follicular lymphoma in adults that has relapsed despite at least two prior treatments. The approval comes following the positive results with the drug in a part of the Phase II clinical trial called the CHRONOS-1 study.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer